The risk of ERCC2 LOF mutations with AdCC is not clear, although some relevant cases have been reported.[5] Preclinical and clinical studies have linked ERCC2 loss of function to cisplatin sensitivity.[9] Studies have reported that pan-cancer patients with DDR dysfunction like BRCA1/2 or ERCC mutations have better OS after immune checkpoint inhibitors treatment.[13,14] For DDR-related mutations, PARP inhibitors may be effective for AdCC, but no reports have been reported so far. This evidence concerns the gene ERCC2 and adrenocortical carcinoma, hereditary.